TRACON PHARMACEUTICALS INC's ticker is TCON and the CUSIP is 89237H209. A total of 34 filers reported holding TRACON PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,673 | -38.8% | 267,821 | +0.0% | 0.00% | – |
| Q2 2023 | $77,906 | -86.5% | 267,719 | -12.5% | 0.00% | – |
| Q1 2023 | $578,015 | +26.0% | 305,828 | -0.7% | 0.00% | – |
| Q4 2022 | $458,852 | -9.5% | 307,954 | +1.3% | 0.00% | – |
| Q3 2022 | $507,000 | -17.0% | 304,088 | -0.4% | 0.00% | – |
| Q2 2022 | $611,000 | -22.5% | 305,410 | +1.9% | 0.00% | – |
| Q1 2022 | $788,000 | -5.6% | 299,621 | -0.6% | 0.00% | – |
| Q4 2021 | $835,000 | -28.0% | 301,484 | +0.7% | 0.00% | – |
| Q3 2021 | $1,159,000 | -39.3% | 299,283 | +1.7% | 0.00% | – |
| Q2 2021 | $1,910,000 | -28.8% | 294,228 | -9.7% | 0.00% | – |
| Q1 2021 | $2,683,000 | -29.6% | 325,970 | 0.0% | 0.00% | – |
| Q4 2020 | $3,813,000 | +13517.9% | 325,970 | +5758.6% | 0.00% | – |
| Q3 2020 | $28,000 | +154.5% | 5,564 | 0.0% | 0.00% | – |
| Q2 2020 | $11,000 | +22.2% | 5,564 | +0.0% | 0.00% | – |
| Q1 2020 | $9,000 | -30.8% | 5,563 | 0.0% | 0.00% | – |
| Q4 2019 | $13,000 | – | 5,563 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 4,764,508 | $9,004,920 | 2.70% |
| Ikarian Capital, LLC | 2,765,530 | $5,226,851 | 1.19% |
| JOHNSON & JOHNSON | 84,003 | $158,766 | 0.05% |
| X-Square Capital, LLC | 17,743 | $34 | 0.02% |
| BOOTHBAY FUND MANAGEMENT, LLC | 258,844 | $489,215 | 0.01% |
| LINDEN ADVISORS LP | 454,916 | $859,791 | 0.01% |
| HoyleCohen, LLC | 13,000 | $24,570 | 0.00% |
| MGO ONE SEVEN LLC | 11,780 | $22,264 | 0.00% |
| Bank of New York Mellon Corp | 66,606 | $125,885 | 0.00% |
| Citadel Advisors | 24,700 | $46,683 | 0.00% |